Skip to main content
. Author manuscript; available in PMC: 2023 Sep 1.
Published in final edited form as: Menopause. 2022 Aug 2;29(9):1021–1027. doi: 10.1097/GME.0000000000002014

Table 2.

Associations of HDP or GDM with total and domain-specific menopausal symptoms among 676 peri- and postmenopausal women a

Model 1 Model 2
β (95% CI)
Model 3
Lifetime history of HDP (no history of HDP [ref])
Total MRS score 0.44 (−0.70 to 1.59) 0.32 (−0.83 to 1.46) 0.13 (−1.02 to 1.27)
Somatic 0.24 (−0.25 to 0.73) 0.19 (−0.30 to 0.67) 0.10 (−0.39 to 0.58)
Psychological −0.05 (−0.59 to 0.48) −0.10 (−0.64 to 0.43) −0.18 (−0.71 to 0.36)
Urogenital 0.26 (−0.13 to 0.64) 0.23 (−0.16 to 0.62) 0.20 (−0.19 to 0.60)
Lifetime history of GDM (no history of GDM [ref])
Total MRS score 0.95 (−0.77 to 2.68) 0.90 (−0.83 to 2.63) 0.50 (−1.24 to 2.25)
Somatic 0.57 (−0.17 to 1.31) 0.54 (−0.20 to 1.28) 0.35 (−0.39 to 1.09)
Psychological 0.34 (−0.47 to 1.14) 0.32 (−0.49 to 1.13) 0.18 (−0.64 to 0.99)
Urogenital 0.05 (−0.54 to 0.63) 0.04 (−0.55 to 0.63) −0.03 (−0.62 to 0.57)

GDM, gestational diabetes mellitus; HDP, hypertensive disorders of pregnancy; MRS, menopause rating scale.

a

Estimates obtained from linear regression models.

Model 1: maternal age at enrollment (18-29 years, 30-34 years, 35-45 years), race/ethnicity (white, black, other).

Model 2: model 1 + college education (yes, no), married/cohabiting (yes, no), annual household income>$70,000 (yes, no), parity at enrollment (nulliparous: yes, no), age at menarche (<12 years, 12-15 years, ≥15 years).

Model 3: model 2 + BMI at midlife (kg/m2).